A number of equities research analysts have recently weighed in on RMTI shares. BidaskClub downgraded Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Zacks Investment Research raised Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, ValuEngine downgraded Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.50.
News headlines about Rockwell Medical (NASDAQ:RMTI) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Rockwell Medical earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 50.4675933076635 out of 100, meaning that recent news coverage is somewhat likely to have an impact on the stock’s share price in the immediate future.
Shares of Rockwell Medical (RMTI) opened at 6.98 on Wednesday. The firm’s market cap is $363.36 million. The stock’s 50 day moving average price is $7.75 and its 200-day moving average price is $6.87. Rockwell Medical has a 12-month low of $3.55 and a 12-month high of $8.98.
Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). Rockwell Medical had a negative return on equity of 36.36% and a negative net margin of 36.35%. The firm had revenue of $14.60 million for the quarter, compared to analysts’ expectations of $12.66 million. During the same quarter in the prior year, the firm earned ($0.10) EPS. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. On average, analysts predict that Rockwell Medical will post ($0.39) earnings per share for the current fiscal year.
Rockwell Medical Company Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.